Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertension and left ventricular hypertrophy

J M Krzesinski1, G Rorive, H Van Cauwenberge

  • 1Service de Néphrologie, C.H.U. Sart Tilman, Liège, Belgium.

Acta Cardiologica
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere®].

Revue medicale de Liege·2022
Same author

[Feasibility and effectiveness study of a simplified mobile self-education and self-monitoring application for patients with severe chronic obstructive pulmonary disease].

Revue medicale de Liege·2022
Same author

[Telemonitoring of severe COPD patients].

Revue medicale de Liege·2019
Same author

[Long-term oxygen therapy: mortality rate, short-term predictive mortality factors].

Revue des maladies respiratoires·2018
Same author

Diagnostic De L'Hypertension Arterielle.

Acta clinica Belgica·2016
Same author

Causes D'Abandon Du Traitement Anti-Hypertenseur.

Acta clinica Belgica·2016
Same journal

Dialysis-related spontaneous anterior mediastinal hemorrhage.

Acta cardiologica·2026
Same journal

From the arrhythmia to the substrate: the role of atrial cardiomyopathy in atrial fibrillation management.

Acta cardiologica·2026
Same journal

Presence of anti-cardiac troponin I antibodies (cTnIAb) and their role in the left ventricular remodelling, in patients with acute myocardial infarction.

Acta cardiologica·2026
Same journal

Guideline-recommended medical therapy and clinical outcomes in cancer patients with de Novo heart failure.

Acta cardiologica·2026
Same journal

Association between red cell distribution width and all-cause mortality in patients with congestive heart failure and atrial fibrillation.

Acta cardiologica·2026
Same journal

The ventricular assist device outflow cannula anastomosis to the descending aorta in a patient with porcelain aorta.

Acta cardiologica·2026
See all related articles

Left ventricular hypertrophy, an abnormal heart structure in hypertension, is a risk factor for heart issues. Reversing this condition with blood pressure treatment may improve outcomes.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Cardiac Physiology

Background:

  • Left ventricular hypertrophy (LVH) is a cardiac adaptation to high blood pressure.
  • The structure of hypertrophied myocardium in hypertension is abnormal and influenced by various factors.
  • LVH is an independent risk factor for adverse cardiovascular events, including sudden death, arrhythmias, ischemia, and heart failure.

Purpose of the Study:

  • To investigate the characteristics and implications of left ventricular hypertrophy in hypertension.
  • To explore the factors influencing the prevalence and anatomical pattern of LVH.
  • To assess the potential benefits of antihypertensive treatment in reversing LVH.

Main Methods:

  • Non-invasive detection and precise characterization of LVH and its anatomical pattern using echocardiography.

Related Experiment Videos

  • Analysis of factors influencing LVH prevalence, including age, gender, weight, race, genetics, and hypertension severity.
  • Review of existing literature on hemodynamic and non-hemodynamic factors affecting cardiac remodeling.

    • Main Results:

    • Echocardiography enables accurate, non-invasive assessment of LVH and its non-uniform anatomical patterns.
    • Hypertension-induced LVH is associated with diastolic dysfunction early in the disease progression.
    • LVH significantly increases the risk of sudden death, arrhythmias, myocardial ischemia, and heart failure.

    Conclusions:

    • Left ventricular hypertrophy in hypertension is a significant independent risk factor for severe cardiovascular complications.
    • Reversibility of LVH through antihypertensive treatment is suggested to be beneficial, supported by preliminary data.
    • Further research is needed to fully elucidate the mechanisms of cardiac remodeling and the impact of treatment.